BiotechTube

Darolutamide (BAY1841788, Nubeqa)

Phase 3Active
0 views this week 0 watching⚡ Active
Interest: 41/100
41
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Biochemically Recurrent Prostate Cancer

Conditions

Biochemically Recurrent Prostate Cancer

Trial Timeline

Apr 3, 2023 → Mar 29, 2030

NCT ID
NCT05794906

About Darolutamide (BAY1841788, Nubeqa)

Darolutamide (BAY1841788, Nubeqa) is a phase 3 stage product being developed by Bayer for Biochemically Recurrent Prostate Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT05794906. Target conditions include Biochemically Recurrent Prostate Cancer.

Hype Score Breakdown

Clinical
17
Activity
12
Company
12
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT05794906Phase 3Active
NCT05059236Phase 2Active

Competing Products

2 competing products in Biochemically Recurrent Prostate Cancer

See all competitors
ProductCompanyStageHype Score
Durvalumab + OlaparibAstraZenecaPhase 2
27
Darolutamide(BAY1841788, Nubeqa) + EnzalutamideBayerPhase 2
32